{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:17Z","timestamp":1792511477021,"version":"4.5.0"},"reference-count":64,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2020,10,2]]},"DOI":"10.1080\/17474086.2020.1817735","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T11:43:48Z","timestamp":1598960628000},"page":"1039-1046","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"13","author":[{"given":"Praveen Ramakrishnan","family":"Geethakumari","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595"},{"key":"cit0002","first-page":"1","volume":"40","author":"Awan FT","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/nri3487"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.12.001"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01454"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-693598"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003632"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"cit0020","doi-asserted-by":"crossref","unstructured":"Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017 Sep 12;1(20):1739\u20131748","DOI":"10.1182\/bloodadvances.2017009720"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-712828"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.002"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1457149"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001883"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15690"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000640"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220590"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547869"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208603"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140806"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1724282"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"issue":"1","key":"cit0039","first-page":"32","volume":"17","author":"Tam CS","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"cit0040","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2019-125483","volume":"134","author":"Cull G","year":"2019","journal-title":"Blood"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125394"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1002\/hon.81_2629"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12779"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-04015-w"},{"key":"cit0046","doi-asserted-by":"crossref","unstructured":"Tam CS, Opat\u00a0S, Zhu J, et al. Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies. [Abstract].EHA library. 2019;2019:3.","DOI":"10.1097\/01.HS9.0000562920.26603.5b"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1719097"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0844"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7572"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/hon.15_2629"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117224"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0163"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000155"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122629"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122628"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125488"},{"key":"cit0057","doi-asserted-by":"crossref","unstructured":"Chen S, Tam CS, Ramsay AG, et al. CLL B cells develop resistance to ibrutinib by reinvigorating the IL-4R - IL-4 axis blocked by bruton\u2019s tyrosine kinase inhibitors including acalabrutinib and zanubrutinib. [Abstract]. Blood. 2019;134:477.","DOI":"10.1182\/blood-2019-127255"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117618"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2667"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1908754"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.014"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2020.1817735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T13:10:16Z","timestamp":1620479416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2020.1817735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,2]]}},"alternative-id":["10.1080\/17474086.2020.1817735"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2020.1817735","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}